Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer
Tian-Qi An, Hui Qiu, Quan-Bo Zhou, Hong Zong, Shuang Hu, Yu-Gui Lian, Rui-Hua Zhao
Tian-Qi An, Hong Zong, Shuang Hu, Rui-Hua Zhao, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China
Hui Qiu, Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing 100000, China
Quan-Bo Zhou, Yu-Gui Lian, Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China
Co-first authors: Tian-Qi An and Hui Qiu.
Co-corresponding authors: Yu-Gui Lian and Rui-Hua Zhao.
Author contributions: Zhao RH, Lian YG and Zong H conceptualized and designed the research; An TQ, Qiu H, Zhou QB and Hu S screened patients and acquired clinical data; Zhao RH, An TQ and Qiu H performed Data analysis; An TQ, Qiu H, Zhao RH, and Lian YG wrote the paper; All the authors have read and approved the final manuscript. An TQ and Qiu H were responsible for patient screening, enrollment, and collection of clinical data. Both authors have made crucial and indispensable contributions towards the completion of the project and thus qualified as the co-first authors of the paper. Both Zhao RH and Lian YG have played important and indispensable roles in the study design, data interpretation and manuscript preparation as the co-corresponding authors. Zhou QB searched the literature, revised and submitted the early version of the manuscript. Hu S and Zong H were instrumental and responsible for data re-analysis and re-interpretation, figure plotting, comprehensive literature search, preparation and submission of the current version of the manuscript. This collaboration between Hu S and Zong H is crucial for the publication of this manuscript and other manuscripts still in preparation.
Institutional review board statement: The study was approved by the Clinical Research Ethics Committee of the First Hospital of Zhengzhou University (No. 2022-KY-0910-001).
Informed consent statement: Patient informed consent was not needed as our study was retrospective.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data are publicly available for sharing use.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Rui-Hua Zhao, PhD, Chief Doctor, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe Road, Zhengzhou 450000, Henan Province, China. zrh_ly@163.com
Received: December 20, 2023
Revised: February 20, 2024
Accepted: April 7, 2024
Published online: June 15, 2024
Processing time: 178 Days and 0.5 Hours
